ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Oncolytics Biotech Inc. Announces Filing Of Phase 1/2 Clinical Trial With REOLYSIN
Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that the U.S.
National Cancer Institute (NCI) has filed a protocol with the U.S. Food
and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients
with metastatic ovarian, peritoneal or fallopian tube cancers using
concurrent systemic and intraperitoneal administration of REOLYSIN®,
Oncolytics' proprietary formulation of the human reovirus. The NCI is
sponsoring the trial under its Clinical Trials Agreement with Oncolytics,
while Oncolytics will provide clinical supplies of REOLYSIN®.
The trial, which is being carried out at The Ohio State University
Comprehensive Cancer Center, is expected to enroll up to 70 patients with
metastatic ovarian, peritoneal or fallopian tube cancers.
These cancer indications were selected after comprehensive preclinical
studies carried out by the NCI indicated the reovirus can kill ovarian
cancer cells.
The American Cancer Society estimates that more than 22,000 women will be
diagnosed with ovarian cancer in the U.S. in 2007, and more than 15,000
will die from it.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of Phase I and Phase II
human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For
further information about Oncolytics, please visit
www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including the Company's expectations
related to the U.S. NCI Phase I/II systemic and intraperitoneal
administration clinical trial for patients with metastatic ovarian,
peritoneal or fallopian tube cancers, and the Company's belief as to the
potential of REOLYSIN® as a cancer therapeutic, involve known and unknown
risks and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds
and resources to pursue research and development projects, the efficacy
of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside
a controlled test, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking
statements. The Company does not undertake to update these
forward-looking statements.
Oncolytics Biotech Inc.
Oncolytics Biotech Inc Announces Depunerea Faza 1 / 2 studiu clinic Cu REOLYSIN - Oncolytics Biotech Inc. Announces Filing Of Phase 1/2 Clinical Trial With REOLYSIN - articole medicale engleza - startsanatate